id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-D-0652-0032,FDA,FDA-2011-D-0652,"The 510(k) Program: Evaluating Substantial Equivalence in Premarket
Notifications; Guidance for Industry and Food and Drug Administration
Staff; Availability",Notice,Notice of Availability,2014-07-28T04:00:00Z,2014,7,2014-07-28T04:00:00Z,,2014-10-26T01:01:37Z,2014-17666,0,0,09000064817e60aa
FDA-2011-D-0652-0033,FDA,FDA-2011-D-0652,"The 510(k) Program: Evaluating Substantial Equivalence in Premarket
Notifications [510(k)]; Guidance for Industry and Food and Drug
Administra tion Staff",Other,Guidance,2014-07-28T04:00:00Z,2014,7,2014-07-28T04:00:00Z,,2024-11-12T05:27:17Z,,1,0,09000064817e7e24
FDA-2011-D-0652-0001,FDA,FDA-2011-D-0652,"Draft Guidances for Industry and Staff; Availability: 510(k) Program, Evaluating Substantial Equivalence in Premarket Notifications; Availability",Notice,Notice of Availability,2011-12-28T05:00:00Z,2011,12,2011-12-28T05:00:00Z,2012-04-27T03:59:59Z,2012-05-25T02:00:27Z,2011-33232,0,0,0900006480f8a26b
FDA-2011-D-0652-0002,FDA,FDA-2011-D-0652,Draft Guidance for Industry and Food and Drug Administration Staff The 510(k) Program Evaluating Substantial Equivalence in Premarket Notifications [510(k)],Other,Guidance,2011-12-28T05:00:00Z,2011,12,2011-12-28T05:00:00Z,2012-04-27T03:59:59Z,2014-09-27T01:07:24Z,,0,0,0900006480f8a513